Recombinant Human OBI1 Protein ，His & Myc

OBI1, or Oligomeric Beta-Interferon 1, is a recombinant protein that has garnered significant attention in biomedical research due to its potential roles in modulating immune responses and treating various diseases, including autoimmune disorders and cancers. As a member of the interferon family, OBI1 is believed to exert its effects through pathways that enhance antiviral activity, promote cell proliferation, and regulate immune functions. The study of OBI1 is particularly relevant given the increasing prevalence of diseases characterized by dysregulated immune responses. Researchers are focusing on its structure-function relationships, therapeutic applications, and the mechanisms underlying its biological activity. Advances in recombinant DNA technology have facilitated the production of OBI1 in various host systems, allowing scientists to explore its pharmacological properties and optimize its therapeutic efficacy. Ongoing studies aim to elucidate the signaling pathways activated by OBI1 and assess its safety and effectiveness in clinical settings, thereby contributing to the development of novel treatment strategies in immunology and oncology. The potential applications of OBI1 extend beyond therapy, as it may also serve as a valuable tool for understanding the complexities of immune regulation, making it a focal point for current and future research in the field.